A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.
Solid Tumors
DRUG: INCB086550
Number of treatment-emergent adverse events, Defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug., Baseline through 90 days after end of treatment, estimated up to 12 months.
Cmax of INCB086550 in fasted and food effect conditions, Maximum observed plasma or serum concentration., Approximately 1 month|tmax of INCB086550 in fasted and food effect conditions, Time to maximum concentration., Approximately 1 month|AUC0-tau of INCB086550 in fasted and food effect conditions, Area under the plasma or serum concentration-time curve from time = 0 to the end of dosing period at steady state, Approximately 1 month|AUC 0-t and/or AUC0-∞ of INCB086550 in fasted and food effect conditions, Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration, or Area under the single-dose plasma concentration-time curve from Hour 0 to infinity, Approximately 1 month|t½ of INCB086550, Apparent terminal-phase disposition half-life., Approximately 1 month|λz of INCB086550, Apparent terminal-phase disposition rate constant, Approximately 1 month|CL/F of INCB086550, Apparent oral dose clearance., Approximately 1 month|Vz/F of INCB086550, Apparent oral dose volume of distribution., Approximately 1 month|Pharmacokinetic/pharmacodynamics correlation, Evaluation of the ability of INCB086550 to modulate PD-L1 expression levels as assessed by flow cytometry protein analyses., Approximately 1 month|Objective response rate, Defined as the percentage of participants having complete response (CR) or partial response (PR) by investigator assessment of radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or response assessment in Neuro-Oncology (RANO)., Every 8 weeks for the duration of study participation; estimated to be 12 months.|Disease control rate, Defined as the percentage of participants having CR, PR, or stable disease ≥ 12 weeks by investigator assessment of radiographic disease assessments per RECIST v1.1 or response assessment in Neuro-Oncology (RANO)., Every 8 weeks for the duration of study participation; estimated to be 12 months.|Duration of response, Defined as the time from the first documented evidence of CR or PR until the earliest date of disease progression by investigator assessment per RECIST v1.1 for response assessment in Neuro-Oncology (RANO), or death due to any cause, if occurring sooner than progression., Every 8 weeks for the duration of study participation; estimated to be 12 months.|Cmin of INCB086550 in fasted and food effect conditions, Minimum observed plasma or serum concentration of INCB086550, Approximately 1 month
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.